Back to Newsroom

Debiopharm Group and TCG Lifesciences Ltd. announce successful completion of first phase of research collaboration on discovery of novel antibiotics

Lausanne, Switzerland and Kolkata, India – June 24 2014 – Debiopharm Group™ (Debiopharm), the Swiss-based global biopharmaceutical company that focuses on the development of prescription drugs that target unmet medical needs, including anti-bacterial, oncology as well as companion diagnostics, and TCG Lifesciences Limited (TCGLS) a leading contract research services company in the area of early drug discovery and development, today announced that they have reached the first research milestone and consequently enter into lead optimization phase for innovative antibiotics targeting drug-resistant bacteria for community and hospital-acquired infections.

Click here to read more